vs
CARRIAGE SERVICES INC（CSV）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是CARRIAGE SERVICES INC的1.3倍（$139.1M vs $105.5M），VERACYTE, INC.净利率更高（20.6% vs 11.6%，领先9.0%），VERACYTE, INC.同比增速更快（21.5% vs 8.0%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 1.0%）
怡和Cycle & Carriage有限公司是怡和集团在东南亚的投资控股公司，目前该集团持有其75%的股份，是怡和集团在东南亚区域开展资本布局与投资业务的核心平台。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CSV vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.3倍
$105.5M
营收增速更快
VCYT
高出13.5%
8.0%
净利率更高
VCYT
高出9.0%
11.6%
两年增速更快
VCYT
近两年复合增速
1.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $105.5M | $139.1M |
| 净利润 | $12.3M | $28.7M |
| 毛利率 | 34.8% | 72.7% |
| 营业利润率 | 23.3% | 16.3% |
| 净利率 | 11.6% | 20.6% |
| 营收同比 | 8.0% | 21.5% |
| 净利润同比 | 24.5% | — |
| 每股收益（稀释后） | $0.76 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSVVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $105.5M | $140.6M | ||
| Q3 25 | $102.7M | $131.9M | ||
| Q2 25 | $102.1M | $130.2M | ||
| Q1 25 | $107.1M | $114.5M | ||
| Q4 24 | $97.7M | $118.6M | ||
| Q3 24 | $100.7M | $115.9M | ||
| Q2 24 | $102.3M | $114.4M |
净利润CSVVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $12.3M | $41.1M | ||
| Q3 25 | $6.6M | $19.1M | ||
| Q2 25 | $11.7M | $-980.0K | ||
| Q1 25 | $20.9M | $7.0M | ||
| Q4 24 | $9.9M | $5.1M | ||
| Q3 24 | $9.9M | $15.2M | ||
| Q2 24 | $6.3M | $5.7M |
毛利率CSVVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 34.8% | 72.5% | ||
| Q3 25 | 35.3% | 69.2% | ||
| Q2 25 | 35.2% | 69.0% | ||
| Q1 25 | 35.3% | 69.5% | ||
| Q4 24 | 34.4% | 66.4% | ||
| Q3 24 | 35.2% | 68.2% | ||
| Q2 24 | 36.2% | 68.1% |
营业利润率CSVVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 23.3% | 26.4% | ||
| Q3 25 | 17.0% | 17.4% | ||
| Q2 25 | 23.5% | -4.0% | ||
| Q1 25 | 29.5% | 2.5% | ||
| Q4 24 | 21.6% | 3.5% | ||
| Q3 24 | 22.7% | 10.4% | ||
| Q2 24 | 18.0% | 4.0% |
净利率CSVVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 11.6% | 29.3% | ||
| Q3 25 | 6.4% | 14.5% | ||
| Q2 25 | 11.5% | -0.8% | ||
| Q1 25 | 19.5% | 6.2% | ||
| Q4 24 | 10.1% | 4.3% | ||
| Q3 24 | 9.8% | 13.1% | ||
| Q2 24 | 6.1% | 5.0% |
每股收益（稀释后）CSVVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.76 | $0.50 | ||
| Q3 25 | $0.41 | $0.24 | ||
| Q2 25 | $0.74 | $-0.01 | ||
| Q1 25 | $1.34 | $0.09 | ||
| Q4 24 | $0.62 | $0.07 | ||
| Q3 24 | $0.63 | $0.19 | ||
| Q2 24 | $0.40 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $254.8M | $1.3B |
| 总资产 | $1.3B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSVVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $1.7M | $362.6M | ||
| Q3 25 | $1.2M | $315.6M | ||
| Q2 25 | $1.4M | $219.5M | ||
| Q1 25 | $4.6M | $186.1M | ||
| Q4 24 | $1.2M | $239.1M | ||
| Q3 24 | $1.3M | $274.1M | ||
| Q2 24 | $1.5M | $235.9M |
股东权益CSVVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $254.8M | $1.3B | ||
| Q3 25 | $242.1M | $1.3B | ||
| Q2 25 | $235.4M | $1.2B | ||
| Q1 25 | $223.1M | $1.2B | ||
| Q4 24 | $208.6M | $1.2B | ||
| Q3 24 | $198.1M | $1.2B | ||
| Q2 24 | $187.9M | $1.1B |
总资产CSVVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.3B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.1M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $6.2M | — |
| 自由现金流率自由现金流/营收 | 5.9% | — |
| 资本支出强度资本支出/营收 | 7.5% | — |
| 现金转化率经营现金流/净利润 | 1.15× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $40.1M | — |
8季度趋势，按日历期对齐
经营现金流CSVVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $14.1M | $52.6M | ||
| Q3 25 | $24.7M | $44.8M | ||
| Q2 25 | $8.1M | $33.6M | ||
| Q1 25 | $13.8M | $5.4M | ||
| Q4 24 | $9.3M | $24.5M | ||
| Q3 24 | $20.9M | $30.0M | ||
| Q2 24 | $2.2M | $29.6M |
自由现金流CSVVCYT
| Q1 26 | — | — | ||
| Q4 25 | $6.2M | $48.8M | ||
| Q3 25 | $18.0M | $42.0M | ||
| Q2 25 | $5.2M | $32.3M | ||
| Q1 25 | $10.6M | $3.5M | ||
| Q4 24 | $4.9M | $20.4M | ||
| Q3 24 | $16.2M | $27.7M | ||
| Q2 24 | $-1.4M | $26.8M |
自由现金流率CSVVCYT
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 34.7% | ||
| Q3 25 | 17.5% | 31.8% | ||
| Q2 25 | 5.1% | 24.8% | ||
| Q1 25 | 9.9% | 3.1% | ||
| Q4 24 | 5.0% | 17.2% | ||
| Q3 24 | 16.1% | 23.9% | ||
| Q2 24 | -1.4% | 23.4% |
资本支出强度CSVVCYT
| Q1 26 | — | — | ||
| Q4 25 | 7.5% | 2.7% | ||
| Q3 25 | 6.5% | 2.1% | ||
| Q2 25 | 2.8% | 1.0% | ||
| Q1 25 | 3.0% | 1.6% | ||
| Q4 24 | 4.5% | 3.5% | ||
| Q3 24 | 4.6% | 1.9% | ||
| Q2 24 | 3.5% | 2.4% |
现金转化率CSVVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 1.15× | 1.28× | ||
| Q3 25 | 3.76× | 2.34× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | 0.76× | ||
| Q4 24 | 0.94× | 4.80× | ||
| Q3 24 | 2.11× | 1.98× | ||
| Q2 24 | 0.34× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
